Abstract Number: 25 • 2012 ACR/ARHP Annual Meeting
Activation of the Canonical Wnt Signaling Pathway Is Tissue Dependent in Osteoarthritic Joints: Distinct Mechanisms of Regulation by Wnt Antagonists
Background/Purpose: Wnt signaling pathway is a major regulator of bone and cartilage remodeling. Modulation of this pathway has lead to controversial results on joint cartilage…• 2012 ACR/ARHP Annual Meeting
Lee C. Howley Sr. Prize for Arthritis Research Introductory Talk I
Abstract Number: L10 • 2012 ACR/ARHP Annual Meeting
In Rheumatoid Arthritis Patients with Stable Low Disease Activity On Methotrexate Plus Etanercept, Continuation of Etanercept 50 Mg Weekly or 25 Mg Weekly Are Both Clinically Superior to Discontinuation: Results From a Randomized, 3-Armed, Double-Blind Clinical Trial
Background/Purpose: The efficacy of etanercept (ETN) in combination with methotrexate (MTX) in the treatment of rheumatoid arthritis (RA) is well established, and long-term trials1 and…• 2012 ACR/ARHP Annual Meeting
Lee C. Howley Sr. Prize for Arthritis Research Introductory Talk II
Abstract Number: L9 • 2012 ACR/ARHP Annual Meeting
Inefficacy of Hydroxychoroquine in Primary Sjögren’s Syndrome: Results of the Joquer Randomized Placebo-Controlled Trial in Primary Sjögren’s Syndrome
Background/Purpose: Hydroxychloroquine (HQ, Plaquenil) is often prescribed in patients with primary Sjögren’s syndrome (pSS), notably for arthralgias, synovitis or purpura, but also only for dryness…Abstract Number: L11 • 2012 ACR/ARHP Annual Meeting
First in Patient Study of Anti-GM-CSF Monoclonal Antibody (MOR103) in Active Rheumatoid Arthritis: Results of a Phase 1b/2a Randomized, Double-Blind, Placebo-Controlled Trial
Background/Purpose: MOR103, a human mAb targeting GM-CSF, is being evaluated for treatment of rheumatoid arthritis (RA). Pre-clinical studies on cytokine function and investigations in experimental…Abstract Number: L12 • 2012 ACR/ARHP Annual Meeting
Short- and Long-Term Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Patients with Rheumatoid Arthritis and an Inadequate Response to TNF Inhibitors: Analyses of Pooled Phase 2, Phase 3, and Long-Term Extension Studies
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor investigated as a targeted immunomodulator and disease-modifying therapy for rheumatoid arthritis (RA). The efficacy and safety…Abstract Number: L14 • 2012 ACR/ARHP Annual Meeting
Treatment of Diffuse Systemic Sclerosis Patients with Anti-Transforming Growth Factor-Beta, Fresolimumab, Inhibits Transforming Growth Factor-Beta-Regulated Gene Expression in Skin and Is Associated with a Rapid Decline in Skin Score
Background/Purpose: Transforming growth factor-beta (TGFb) has long been suspected to mediate fibrotic signals in systemic sclerosis (SSc) as it potently stimulates collagen deposition in vitro,…Abstract Number: L13 • 2012 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results of a Phase 3, Randomized, Controlled Trial
Background/Purpose: Apremilast, an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate a network of pro- and anti-inflammatory mediators, including those implicated in the etiopathogenesis of…Abstract Number: L6 • 2012 ACR/ARHP Annual Meeting
Blisibimod, an Inhibitor of B Cell Activating Factor, in Patients with Moderate-to-Severe Systemic Lupus Erythematosus
Background/Purpose: To evaluate the efficacy, safety, and tolerability of subcutaneously-administered blisibimod (A-623, AMG 623), an inhibitor of soluble- and membrane-bound B-cell activating factor (BAFF), in patients…Abstract Number: L3 • 2012 ACR/ARHP Annual Meeting
Classification Criteria for Systemic Sclerosis: Preliminary Results
Background/Purpose: The existing 1980 classification criteria for systemic sclerosis (SSc) are suboptimal for patients with early SSc and some patients with limited cutaneous SSc (lcSSc)…Abstract Number: L2 • 2012 ACR/ARHP Annual Meeting
High Dose Immunoablation and Autologous Hematopoietic Stem Cell Transplantation Versus Monthly Intravenous Pulse Therapy Cyclophosphamide in Severe Systemic Sclerosis
Background/Purpose: High dose immunosuppressive therapy and hematopoietic stem cell transplantation (HSCT) have shown efficacy in severe systemic sclerosis (SSc) in phase I and II trials.…Abstract Number: L4 • 2012 ACR/ARHP Annual Meeting
Continued Improvement of Signs and Symptoms in Patients with Active Psoriatic Arthritis: Week 52 Results of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study
Background/Purpose: PSUMMIT I ,through wk24, demonstrated efficacy and safety of ustekinumab (UST) in reducing signs and symptoms of active psoriatic arthritis (PsA) in a large,…Abstract Number: L1 • 2012 ACR/ARHP Annual Meeting
A Randomized, Placebo-Controlled Phase 2 Study of ARRY-797 in Patients with Osteoarthritis Pain Refractory to NSAID Treatment Showed Statistically Significant Improvements in WOMAC Pain and in Biomarkers of Bone and Cartilage Degradation
Background/Purpose: Osteoarthritis (OA) is the most common chronic joint disease and OA pain is a leading cause of work disability. p38 inhibition suppresses the production…Abstract Number: L7 • 2012 ACR/ARHP Annual Meeting
Tapering TNF-Blockers in Established Rheumatoid Arthritis Patients in DAS28 Remission: Results of a DAS28-Driven Step-Down Strategy Randomized Controlled Trial
Background/Purpose: Step-down therapeutic strategies are often considered in established rheumatoid arthritis (RA) once remission is achieved but are associated with a potential risk of relapse…
ACR Meeting Abstracts